|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John Buchan reviews best practices for achieving quality by addressing challenges focused on the all-important but growing complexity of managing the distribution of critical safety documents and the processing of Individual Case Study Reports and aggregate reports to sites, Ethic Committees (ECs), IRBs, and others in the reporting chain.
|
|
|
Jeffrey Tillack, Chief Operating Officer at Credence MedSystems, discusses the challenges being addressed by his innovative technology and the role its new Flex Line will play in the company’s scaling strategy.
|
|
|
Matthew A. Clark, PhD, says despite this high level of interest, there remains variable understanding of how to maximize the potential of a DEL screen, and shares his company’s approach to DEL screening and how its partners get the most from this powerful technology.
|
|
|
Jeremy R. Graff, PhD, says new studies show promising data with the use of mRNA-based vaccines and the injection of nanoparticles into regional lymph nodes to achieve disease stabilization. This has led to a potentially groundbreaking era of therapeutic cancer vaccines thanks to discoveries in identifying truncal targets, targeting tumor neoantigens and, notably, developing improved delivery technologies that stimulate a robust, targeted, and persistent immune response.
|
|
|
Christopher Worrall, PhD, discusses how nanoparticle engineering technologies could help improve compliance and patient outcomes, for both small-molecule and biological drugs, and how nanotechnology can help facilitate a shift toward more patient-centric medicine.
|
|
|
Atul Lohade, PhD, Vinay Muley, and Tejas Gunjikar, PhD, explain how understanding the challenges associated with developing smaller extended-release tablets, and the excipient-based solutions to these challenges, will empower formulators to develop robust, stable drug formulations with high patient adherence while cutting manufacturing costs.
|
|
|
|
|
|
|
|
|

Lonza CHI is a preferred global partner to the pharmaceutical, biotech and nutraceutical markets. Our pioneering Capsugel® capsules and encapsulation technologies help improve speed of development and execution and the match of dosage form performance to ingredients or API application. Our product portfolio and product services for pharmaceutical partners include capsules (including customizations), equipment, and ingredient/API formulation services. Click here for more.
|
|
|
|
|
|
 |
|
The Pistoia Alliance recently announced the launch of the Clinical Trials Environmental Impact Community of Interest (CoI) to measure and compare the carbon footprint of centralized (traditional site-based) and decentralized clinical trials…..
|
|
 |
|
VBI Vaccines Inc. and Agenus recently announced a collaboration to evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, and balstilimab, Agenus’ monoclonal….
|
|
 |
|
Tavros Therapeutics and Vividion Therapeutics, Inc. recently announced the companies have entered into a collaboration agreement to discover or target four oncology targets across an initial 5-year term…..
|
|
 |
|
Syneos Health recently announced an expanded partnership with Datavant, the leader in helping organizations securely connect health data. The increasing collaboration between the companies will further leverage….
|
|
|
|
|
|
|
|
 |
|
Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….
|
|
 |
|
In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.
|
|
|
|
|
|
|
|
 |
|
Synchronizing and controlling API delivery, Extrusion-Spheronization (E-S) offers pharmaceutical drug developers a robust technique to develop and manufacture today’s most complex oral sold dose therapeutics.
Manufacturing oral solid dose API’s into spheres via Extrusion-Spheronization is not new. What is …
|
|
 |
|
In today’s fast-growing biopharma market, injectable medications have become a powerful driver of growth and innovation. Within that sector, industry leaders are increasingly focused on one key area: integrating a drug product and a delivery device. As the market expands …
|
|
|
|
|
Upcoming eNewsletter Features:
October 26 – Formulation Development
November 2 – Prefilled Syringes
|
|
|
|
|
|
|
|